Group 1 - The core viewpoint of the news is that Anjiasi's stock price has increased by 6.07% to 87.93 yuan, with a rolling PE ratio of 24.14, marking a new low in 318 days, and a total market capitalization of 7.12 billion yuan [1] - Anjiasi ranks 48th in the medical device industry, which has an average PE ratio of 59.32 and a median of 39.97 [1] - As of July 31, 2025, Anjiasi has 5,365 shareholders, an increase of 202 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Anjiasi specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with main products including GI, EMR/ESD, and ERCP diagnostic series [1] - The company has received multiple government honors, including the title of "Zhejiang Province Export Brand" and the "Quality Award" from the Linping District Government [1] - In the latest semi-annual report for 2025, Anjiasi achieved an operating income of 302 million yuan, a year-on-year increase of 14.56%, and a net profit of 126 million yuan, with a gross profit margin of 70.21% [1]
安杰思收盘上涨6.07%,滚动市盈率24.14倍,总市值71.20亿元